Emergence of Fluoroquinolone Resistance in Mycobacterium tuberculosis during Continuously Dosed Moxifloxacin Monotherapy in a Mouse Model-Reference-Cited by-同舟云学术

Emergence of Fluoroquinolone Resistance in Mycobacterium tuberculosis during Continuously Dosed Moxifloxacin Monotherapy in a Mouse Model

Published:2005-09 Issue:9 Volume:49 Page:3977-3979
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ginsburg Amy Sarah¹,Sun Ronggai²,Calamita Heather³,Scott Cherise P.¹,Bishai William R.¹,Grosset Jacques H.¹

Affiliation:

1. Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland

2. AERAS Global TB Vaccine Foundation, Bethesda, Maryland

3. United States Patent and Trademark Office, Washington, D.C.

Abstract

ABSTRACT Fluoroquinolone resistance in tuberculosis may rapidly emerge. Mice infected with high titers of aerosolized Mycobacterium tuberculosis and treated for 8 weeks with four concentrations of moxifloxacin (0.125, 0.25, 0.50, and 1.0%) mixed into the diet had drug concentrations of 2.4, 4.1, 5.3, and 17.9 μg/ml, respectively, in blood. Selection of fluoroquinolone-resistant mutants occurred in all surviving mice.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.49.9.3977-3979.2005

Reference14 articles.

1. Bozeman, L., W. Burman, B. Metchock, M. Weiner, and F. Gordin. 2002. Fluoroquinolone susceptibility among selected Mycobacterium tuberculosis isolates from the United States and Canada. Am. J. Respir. Crit. Care Med.165(Suppl.):A18.

2. Ginsburg, A. S., J. H. Grosset, and W. R. Bishai. 2003. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis.3:432-442.

3. Ginsburg, A. S., N. Hooper, N. Parrish, K. E. Dooley, S. E. Dorman, J. Booth, M. Diener-West, W. G. Merz, W. R. Bishai, and T. R. Sterling. 2003. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin. Infect. Dis.37:1448-1452.

4. Ginsburg, A. S., S. C. Woolwine, N. Hooper, W. H. Benjamin, Jr., W. R. Bishai, S. E. Dorman, and T. R. Sterling. 2003. The rapid development of fluoroquinolone resistance in M. tuberculosis. N. Engl. J. Med.349:1977-1978.

5. Hong Kong Chest Service/British Medical Research Council. 1992. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tuber. Lung Dis.73:59-67.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study of Structurally Diverse Currently Used and Recently Developed Antimycobacterial Drugs;Medicinal Chemistry;2023-08

2. Moxifloxacin-Mediated Killing of Mycobacterium tuberculosis Involves Respiratory Downshift, Reductive Stress, and Accumulation of Reactive Oxygen Species;Antimicrobial Agents and Chemotherapy;2022-09-20

3. Whole-genome sequencing for surveillance of fluoroquinolone resistance in rifampicin-susceptible tuberculosis in a rural district of Shanghai: A 10-year retrospective study;Frontiers in Public Health;2022-09-15

4. Moxifloxacin-mediated killing of Mycobacterium tuberculosis involves respiratory downshift, reductive stress, and ROS accumulation;2022-04-04

5. Study of Various Chemically and Structurally Diverse Currently Clinically Used and Recently Developed Antimycobacterial Drugs;Molecular Epidemiology Study of Mycobacterium Tuberculosis Complex;2021-09-15